General Information of Drug (ID: DMPOAB7)

Drug Name
1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one Drug Info
Synonyms
3654-49-7; (1E,4E)-1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one; 1,5-Bis(4-hydroxyphenyl)penta-1,4-dien-3-one; Bis-1,5-(4-Hydroxyphenyl)-1,4-Pentadien-3-one; 1,5-Bis-(4-hydroxyphenyl)-1,4-pentadien-3-one; CHEMBL129134; EINECS 222-896-4; AC1O5NFJ; 1,5-Di(p-hydroxyphenyl)-1,4-pentadien-3-one; 1,5-BIS(4-HYDROXYPHENYL)-1,4-PENTADIEN-3-ONE; 4,4'-Dihydroxydistyrylketon; ZINC6092599; BDBM50067044; AKOS015962226; CD-1056; M064; CC-03405; AC-16155; A823289; C-35230; 654B497; 1,5-Bis-(4-hydroxy-phenyl)-penta-1,4-dien-3-one; W-106603
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6437306
CAS Number
CAS 3654-49-7
TTD Drug ID
DMPOAB7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glutethimide DMGE0CW Insomnia 7A00-7A0Z Approved [2]
ISOQUINE DMR17YI Malaria 1F40-1F45 Phase 1 [3]
ICI-199441 DMEWZ80 Discovery agent N.A. Investigative [4]
ML-3163 DM3S5UC Discovery agent N.A. Investigative [5]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 Discovery agent N.A. Investigative [6]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG Discovery agent N.A. Investigative [7]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ Discovery agent N.A. Investigative [8]
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol DMUGAT8 Discovery agent N.A. Investigative [8]
4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol DMK4ICB Discovery agent N.A. Investigative [8]
4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine DM9UGO0 Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Debrisoquine 4-hydroxylase (CYP2D6) TTVG215 CP2D6_HUMAN Inhibitor [1]

References

1 Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
2 A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78.
3 Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15.
4 Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52.
5 Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
6 Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
7 Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
8 New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
9 Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6.